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Background: Adaptations to evidence-based substance abuse treatment programs may impact their effectiveness.
A qualitative study of MET/CBT-5 implementation in community agencies treating adolescents found that the
majority of the agencies made adaptations and that the most frequent adaptation was to provide more than five
treatment sessions.
Methods: Baseline and outcome data from SAMHSA’s Effective Adolescent Treatment demonstration were
analyzed to assess associations between length of treatment, client characteristics, and outcomes at three months.
Results: Adolescents who received more or less than the protocol length of 5 sessions were less likely to be
discharged to the community than those who received the 5 session protocol. Those who received more than five
sessions were more likely to have higher severity scores at intake but almost 50% of those with more than five
sessions had low intake severity scores. Clients who received less than five sessions tended to have lower severity
scores than clients who received more than five sessions.
Conclusions: Length of treatment tended to vary by site rather than severity of substance problems or frequency
of use. There was no significant improvement of substance abuse problems or decrease in frequency of use
with longer treatment. Implementation of the MET/CBT-5 component of the Cannabis Youth Treatment trial in
the EAT project illustrates the difficulty of adherence to an evidence based protocol in the field.
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Development and implementation of evidence-based
treatment for substance-abusing adolescents is critical
because adolescents who use drugs are more likely to
suffer from dependence in their lifetime [1]. The Sub-
stance Abuse and Mental Health Services Administra-
tion (SAMHSA), Center for Substance Abuse Treatment
(CSAT) sponsored the Cannabis Youth Treatment
(CYT) trial [2] to test and compare five models of care.
Subsequently, the Effective Adolescent Treatment (EAT)
program supported replication and expansion of the
most cost-effective model of care – MET/CBT-5 (two* Correspondence: rileyk@ohsu.edu
1Public Health & Preventive Medicine, Oregon Health & Science University,
Portland, OR, USA
3Department of Public Health & Preventive Medicine, CB669, Oregon
Health & Science University, 3181 SW Sam Jackson Park Road, CB669,
Portland, OR 97239-30, USA
Full list of author information is available at the end of the article
© 2012 Riley et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the orsessions of motivational effectiveness treatment (MET)
plus three sessions of cognitive behavioral treatment
(CBT)).
Implementation of evidence-based practices generally
requires acceptance of new procedures—a change from
the usual. An organization’s structure, norms, and
decision-making processes can affect diffusion and
characteristics of newly implemented interventions.
Compatibility with current practice, complexity of the
intervention, timing, communication, and the charac-
teristics of the innovation affect implementation [3].
A review of implementation research and the difficulties
faced in introducing new programs and determining
their impact noted progress in increasing the use of
evidence-based practices but “the science related to
implementing these programs with fidelity and good
outcomes for consumers lags far behind” (p. vi) [4].
Fidelity of implementation is as important for outcome
as the quality of the treatment. An analysis of recidivismd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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implemented was no better than poor treatment imple-
mented extremely well [5,6]. Programs should optimally
choose the strongest intervention that they can imple-
ment well.
Implementing and evaluating an evidence-based sub-
stance abuse treatment intervention is challenging. To
maintain fidelity in Multidimensional Family Therapy
(MDFT), Liddle et al. provided a six-month training
period with regular supervision, co-therapy sessions, and
booster meetings [7,8]. Similarly, an implementation
study of Functional Family Therapy (FFT) included two
years of counselor training and weekly consultation
using a conceptual framework of adoption of innova-
tions with attention to the complex influences on imple-
mentation [9]. Some clinicians, however, had difficulty
accepting the model and wanted to provide additional
services [9].
Many counselors believe that longer treatments are
required. Based on previous research, the National Insti-
tute of Drug Abuse (NIDA) recommended at least
90 days of treatment to support stable recovery [10]. In
contrast to these recommendations, treatment for ado-
lescents has a history of limited duration because more
than 50% of adolescents drop out of treatment within
6 weeks [11].
The limited contact of adolescents with treatment was
recognized in the design of the Cannabis Youth Treat-
ment (CYT) randomized clinical trial. The study tested
five adolescent treatment programs of varying lengths. In
addition to four 12–13 week programs (Family Support
Network [FSN], Adolescent Community Reinforcement
Approach [A-CRA], MDFT, and MET/CBT-12), brief
(6–7 week) outpatient treatment of adolescents was
included because over 75% of adolescents receive that
much or less in the public treatment system [12]. The
five session MET/CBT-5 substance abuse treatment
model had results similar to the other four programs and
was one of the most cost-effective and cost-beneficial
models [12,13].
CSAT selected MET/CBT-5 for a post randomization
replication study in 38 Effective Adolescent Treatment
(EAT) awards. CSAT and the National Institute on Alco-
hol Abuse and Alcoholism (NIAAA) supported a quali-
tative study of implementation in nine EAT sites. In
depth, quarterly interviews of staff at 9 sites indicated
that although agency counselors and supervisors were
trained and certified in the manualized MET/CBT-5
protocol, almost all sites made adaptations [14]. Some
modified the protocol to address individual client needs
such as multiple drug use, streetwise clients, ethnic sub-
cultures, and gender differences. One agency added
psychiatric sessions for clients with a co-occurring diag-
nosis of mental health issues. Additional adaptationswere made to adjust to agency and client pressures,
including delivery of the CBT portion on an individual
basis to avoid scheduling conflicts or transportation
barriers and the inability to bring clients together in
groups. Several agency representatives reported that
onsite supervision sessions gradually declined in fre-
quency because the counselor or the supervisor was
busy or had confidence in the counselor’s ability to per-
form as trained [14]. The most frequent adaptation was
the addition of more treatment sessions, sometimes in
response to parental or referring agency requests for
more treatment [14]. The EAT clients had a larger pro-
portion of minority clients than the CYT sample, were
less likely to have their primary substance as marijuana,
and had a greater range of substance abuse and mental
health issues but the mean levels of severity were similar
to the CYT study [15].
The current study used data that were available from
EAT sites to assess relationships between treatment
length, client characteristics and treatment outcomes.
Two research questions were examined:
 What were the characteristics of clients who
received more treatment and do the differences
indicate that more treatment was needed for those
who received it?
 Did the clients who received longer treatment have




Clients enrolled in EAT programs completed the Global
Appraisal of Individual Needs (GAIN) [16] to record
intake status and to assess change over time. The GAIN
includes multiple assessment instruments [16] and
has been used in varied settings and projects [2,17]. The
GAIN-I, the initial assessment, was administered by
counselors that received either one week of training off-
site or received training on-site from certified local trai-
ners. Clients provided self-reports to the counselors in
50–120 minute individual sessions. Counselors submit-
ted audiotapes from their agency sessions for trainer
review and certification of counselor competency. The
counselors also received weekly supervision from agency
staff who were trained and certified in the GAIN and in
GAIN supervision. The GAIN-M90 (a shorter, monitor-
ing version) was administered in the same individual
manner by a counselor 90 days after intake.
The GAIN TTL (Treatment Transition Log) docu-
mented the date of admission and discharge for each
level of care (e.g., outpatient, intensive outpatient, short
term residential), including prior level of care, referral
source, current level of care, the type of treatment
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discharge status. Discharge and admission dates were
subtracted to calculate treatment duration [18].
The GAIN 2007 dataset of client level data from
the EAT cohort was used for this study. Permission
was requested of the EAT grantees to use their data in a
de-identified dataset. The Oregon Health & Science
University’s Human Subjects Institutional Review Board
determined the secondary analysis met criteria for
exemption. Usable data were available from 36 sites with
6,527 clients who had participated in follow-up assess-
ments 3 months after intake. Clients who were assessed
at the 3- and 6-month follow up interviews were com-
pared to determine whether those who did not complete
the 6-month follow up (n = 618) were significantly differ-
ent than those who completed it. Clients who were not
available for the 6-month follow-up tended to be older
than the predominant group of 14–17 year olds
(χ2
2 = 24.14); no other differences were significant. Based
on the lack of major differences and the desire to have
the largest number of clients for analysis, the 3- month
follow-up group was selected for further analysis.
Clients were excluded if they did not receive
METCBT5 in an outpatient setting (n = 79), were not
in outpatient treatment (n = 392), had no record of
EAT treatment at 3 months (n = 749), and did not have a
3-month follow-up record (n = 2,187), leaving a total of
3,988 clients. Clients who had 0 sessions recorded for
the length of treatment (N = 1,135) or were missing the
length of treatment (N = 389) were excluded from
the analysis. Also excluded were those who were still in
treatment (n = 105) and those who left against staff
advice (ASA) or against medical advice (AMA) (n = 244).
Those with missing data for the General Individual
Severity Scale (GISS) (n = 60) and race (n = 2) were also
excluded. These exclusions further reduced the sample
size to 2,053 clients at 34 sites. See Figure 1. Final sample
size used for each analysis is listed in the relevant sections.
Key variables
Demographic characteristics included gender, age, race/
ethnicity, current criminal justice involvement, and pri-
mary substance used.
Client severity: Clients who entered treatment with
higher scores on measures of behavior, mental, sub-
stance frequency use, and/or substance problems at in-
take baseline were considered to potentially have more
difficulty in responding positively to substance abuse
treatment than clients with lower scores. The General
Individual Severity Scale (GISS) assessed problem sever-
ity [19] by counting symptoms across 15 scales (123
items, coded as 0-28 = 0, 29-50 = 1, 51-123 = 2 with
higher scores indicating greater severity; alpha of .97 in
adolescents): The items form four dimensions:Behavior Complexity Scale (BCS): (alpha = .94, mean
10.57, sd = 8.363) BCS scores range from 0 to 33. BCS
scale cutoff scores were categorized as 0–5, 6–18, and
19–33. A count of external behavioral problems, such as
fidgeting, being forgetful, being disorganized, avoiding
things that took too much effort, starting fights, setting
fires, vandalism, running away, etc., reported in the past
year. Higher scores represent increasing difficulty control-
ling external behavior (e.g., ADHD, Conduct Disorder).
Internal Mental Distress Scale (IMDS): (alpha = .94,
mean = 8.28, sd = 8.785) IMDS scores range from 0 to
43. Cutoff scores were categorized as 0–8, 9–23, and
24–43. Count of symptoms including somatic, anxiety,
depression, traumatic stress and suicide/homicide. Higher
scores are associated with risk for suicide and violence.
Substance Frequency Scale (SFS8p- abbreviated to SFS
for this study): (alpha = .79, mean = .12, sd = .14). Cutoff
scores were categorized as 0, 0.01-0.13, and 0.14-1.00.
Average percent of days (of the past 90) reported for any
alcohol or other drug (AOD) use; heavy AOD use; pro-
blems from AOD use; and days of alcohol, marijuana,
crack/cocaine, heroin/opioid, and other drug use. Higher
scores represent increasing frequencies of substance use
in terms of days, days staying high most of the day (i.e.,
high risk of problems), and days actually causing pro-
blems. People with scores over .14 may have consider-
able difficulty stopping without significant assistance
and/or a controlled environment.
Substance Problem Scale - Past Month (SPSM):
(alpha = .89, mean = 2.58, sd = 3.492) Scores range from
0–16. The cutoff scores were categorized as 0, 1–9, and
10–16. Three subscales were examined: Substance Issues
Index in the past month [SIIM], Substance Abuse Index
in the past month [SAIM], and Substance Dependence
Scale in the past month [SDSM]). The SIIM includes a
count of symptoms of substance related problems in-
cluding two for substance-induced health and psycho-
logical problems, and three on lower severity symptoms
of use (hiding use, people complaining about use, weekly
use) that a client reports having in the past month. The
SAIM includes a count of symptoms of substance abuse
in the past month that were endorsed by the client.
The SDSM includes a count of symptoms of substance
dependence in the past month that were endorsed
by the client. Interpretation: Higher SPSM scores repre-
sent greater severity of drug problems. The scale
includes physiological, psychological, and social criteria,
as well as an item on co-morbid use with drugs that
is likely to exacerbate the other problems. It is associ-
ated with increased odds of externalizing and internaliz-
ing problems.
Crime/Violence Scale (CVS): (alpha = 0.90, mean =
3.128, sd = 5.987) The cutoff scores were categorized as
0–2, 3–6, and 7–31. Count of strategies used during the
N = 6,527 
Subset to 3,988 (3,988/6527 = 61%) 
Clients that received METCBT5 in an outpatient
setting, with 3-month follow-up treatment data and
were due for a 6-month follow-up
3,988 – (1,028 = 2,2441,135+389) = 2,464 
Clients who had 0 sessions or were missing no. 
of sessions recorded for the length of treatment
variable (S7e4_3) were excluded. 
(N for Table 1) 
2,244 – (105+244) = 2,115 
Clients who were not discharged or left 
ASA/AMA (Against Staff Advice/Against 
Medical Advice) were excluded
(N for Table 2) 
2,115 – 62 = 2,053 
Those who were missing data for GISS
(n=60) and race (n=2) were excluded.
Final Analytic N for discharge to the 
community analysis = 2,053
(N for Table 3)
Figure 1 Client exclusion data analysis flow chart.
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property, drug related, and interpersonal crimes commit-
ted. The scale is designed to predict future crime and
violence [19,20]. This measure was only included on the
initial GAIN. Higher values indicate greater involvement
in illegal activities, and/or more violent strategies.
Clients with low GISS scores (0) are unlikely to need ser-
vices. Clients with Moderate scores (1) and who have a
possible diagnosis are likely to benefit from a brief interven-
tion. Higher GISS scores (2) have a high probability of
diagnosis and need more formal assessment and interven-
tion. High scores are indicative of more severe problems in
substance use, mental and physical health, and illegal
activities [19,20]. (A more detailed description of these and
other GAIN scales can be obtained at http://www.chestnut.
org/LI/gain/index.html#supporting%20psychometrics,
%20scales,%20and%20crosswalks). The GISS scale was
administered at intake and subscales were included in the
M90 assessment 90 days after intake.
Length of treatment: The MET/CBT-5 protocol speci-
fies five sessions of care. The variable ‘how many times
did you go to a regular outpatient program’ (s7e4_3) was
used to code the number of sessions based on the client’s
self report. To designate adherence to the protocol length,
the number of sessions was coded as less than five ses-
sions (1–4), five sessions, and greater than 5 sessions.
Sites: The CYT study found that site effects were im-
portant [12] In the qualitative analysis, EAT sites also
appeared to differ based upon offering a predominant
pattern of treatment length [14]. Site characteristics were
considered as possible influences on length of treatment;
e.g., staff culture emphasizing longer treatment, reim-
bursement per session, or predominant characteristics of
clients could influence counselors to add sessions. Avail-
able site information was reviewed to determine if there
were any different patterns. Sites were provided with a
flat payment rather than payment per client visit and
counselor attitudes and site culture were not measured
in the study. To control for possible unmeasured influ-
ences, therefore, the 34 sites were included as a nominal
variable in the multinomial logistic regression and as a
randomized effect in the multi-level mixed-effects logis-
tic regression modeling.
Outcome measures:
Discharge Status: Completed clients were dichotomized
based on discharge destination. Discharge to the
community was considered the optimum treatment
result. All other discharge categories required
continuing treatment or justice involvement and
were combined.
Substance problems: Self report of substance abuse
problems and substance abuse frequency at 3-monthfollow-up were used to determine whether clients
were still experiencing problems with substance use
after or close to completion of treatment. Because the
GISS scale was only administered at intake, the SFS
and SPSM subscales at intake were compared with
their 3-month follow up scores to determine if changes
in usage or problems might be an indicator of outcome
success. The SFS scale provides information on average
percentage of days reported of alcohol or drug use in
the past 90 days. The SPSM scale provides an indicator
of substance problems. Both scales can also be used to
compare substance activities at two different points in
time. The variables SPSM and SFS at intake, described
in the GISS variable section, were compared with
scores on these variables at 3-month follow up to
determine whether substance use and frequency had
increased, remained the same, or decreased after that
time period had elapsed and treatment had been
completed to see whether those outcomes were
associated with discharge status and length of
treatment.
Data analysis
Characteristics of excluded clients were compared with
the final sample to determine if there were significant
differences using Pearson’s χ2 test. For the final sample
contingency tables and Pearson’s χ2 test were used to
examine the associations between client characteristics
and length of treatment (5 sessions, <5 sessions, and >5
sessions). Client characteristics included baseline age,
race, gender, primary substance used, GISS scores at
intake, baseline scores of 5 subscales (IMDS, BCS, SFS,
and SPSM), 3-month scores of 2 subscales (SFS and
SPSM), and criminal justice involvement at baseline.
ANOVA was used to test whether the mean of the con-
tinuous variable CVI differed by length of treatment.
Associations were also examined between discharge status
and client characteristics that included treatment length,
gender, race, baseline age, GISS, and three month SPSM
and SFS scores at three-month follow up. In these anal-
yses SPSM and SFS were used as dependent variables.
A multi-level mixed effects logistic regression model
[21] was used to test whether treatment length was asso-
ciated with discharge to the community after adjusting
for client characteristics. Client characteristics included
baseline age, race, gender, GISS at intake, 3-month
SPSM and SFS scores, and site. Site was treated as a ran-
dom effect to accommodate for the varying baseline
covariates at each site. To assess for colinearity, correl-
ation was checked using Pearson’s correlation coeffi-
cient, between the 3-month SPSM scores, 3-month SFS
scores, and the length of treatment variable.
To assess whether treatment length was associated
with substance use outcomes at 3 months after adjusting
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model was used. Separate models for 3-month SPSM
scores and 3-month SFS scores were run with the same
set of adjustments in each model. Adjustments included
baseline age, race, gender, and GISS at intake. All 34
sites were included as a nominal variable. All data ana-
lyses were conducted using STATA 11.0 [22].
Results
Descriptive analysis- client characteristics
In comparing the final sample with clients who were
excluded from the analysis, the final sample tended to be
younger (X2
2 = 12.352, p = .002) and clients were more
likely to be white than minority (X1
2 = 20.93, p < .001).
In addition, their primary abuse substance was more
likely to be alcohol or marijuana whereas those who
were excluded were more likely to use other drugs
(X3
2 = 17.9159, p < .001). There were also differences in
problem severity with clients in the final sample having
moderate baseline severity scores in comparison with
excluded clients who tended to have lower overall scores
(X2
2 = 12.1696, p = .002), including moderate baseline
behaviorial conflict (X2
2 = 32.1688, p < .001) and sub-
stance use frequency scores (X2
2 = 10.6907, p = .005) in
comparison with lower scores for excluded clients. At
three month follow-up the final sample had lower sub-
stance use frequency scores and those who were
excluded had higher frequency of usage (X2
2 = 17.3637,
p < .001). There were no differences in gender, criminal
justice involvement, baseline internal mental distress and
substance problems, or three month substance problems.
In the final sample at 3-month follow-up, almost half
of the discharged adolescents had received more than 5
sessions (45%), one-third received 5 sessions (34%), and
almost a quarter (22%) received less than 5 sessions.
See Table 1. Younger (χ4
2 = 14.83, p = .005), non-white
(χ2
2 = 7.46, p = .024) clients were more likely to receive
less than 5 sessions. Clients who had criminal justice
involvement at intake were more likely to receive add-
itional treatment than the protocol number of sessions
(χ2
2 = 38.12, p < .001). Clients who used marijuana were
more likely to receive 5 sessions or less and clients using
“other drugs”, including inhalants and narcotics, were
more likely to receive additional sessions (χ2
2 =45.81,
p < .001). An examination of site characteristics for sites
that predominantly provided less than 5 sessions, 5 ses-
sions, or more than 5 sessions determined that there
were no patterns that differentiated one group from
another in terms of population or racial composition of
their cities or other characteristics. However, the 6 sites
that offered predominantly fewer sessions to 60% of
their clients tended to have a small number of clients
and averaged only 31 clients per site and 3 of the sites
had not provided the 5 session protocol to anyone,including two sites that only had one client each. In con-
trast, 11 sites predominantly provided the 5 session
protocol and 17 sites predominantly provided more than
5 sessions. The average number of clients served at
those sites was similar for both of these two groups;
76 and 68 respectively. However, 70% of the clients in
the first group predominantly received the protocol
length of treatment whereas 72% of the clients in the last
group received more than 5 sessions.
Associations between baseline GISS scores and length
of treatment indicated that most clients (52%) had low
severity scores at intake. Adolescents with higher sever-
ity scores were just as likely to receive more or less than
five sessions and those with low scores were more likely
to receive five sessions or less than the recommended
number of sessions (χ4
2 = 24.63, p < .001). Clients with
moderate severity scores were slightly more likely to
be associated with receiving 5 sessions or more. Signifi-
cant associations with length of treatment were also
found for the component GISS scales of Crime Violence
(F2, 2458 = 7.72, p < 0.001), Internal Mental Distress
(χ2
2 =17.82, p < .001), Behavioral Complexity (χ2
2 =20.19,
p < .001), and SPSM (χ2
2 =13.47, p < .001), although most
clients had moderate or low scores. Most clients had
higher scores on the SFS scale and those with the high-
est scores were more likely to receive more sessions
(χ2
2 =40.29, p < .001). However, many clients in the group
of high or moderate scorers for this variable received
less than the protocol number of sessions.
Substance problems and frequency of use at 3 months
after intake were significantly associated with number
of sessions received. Increased substance problems
(χ4
2 = 13.46, p = .009) was associated with receiving more
treatment sessions, although there were still many in the
high scoring category that received fewer sessions than
the protocol length of five sessions. Increased frequency
of use was associated with both receiving less than and
more than the protocol number of sessions (χ4
2 = 21.49,
p < .001).
Discharge outcomes and length of treatment
Length of treatment was associated with discharge des-
tination among the completed EAT clients (χ2
2 = 139.53,
p < .001). See Table 2. Overall, a majority of clients were
discharged into the community (81%; 1,710 of 2,115).
Of the clients who received the protocol length of treat-
ment (5 sessions), 93% were discharged into the com-
munity, compared to 82% of those with less than 5
sessions of treatment and 70% of those who received
more than 5 sessions. Race/ethnicity was not associated
with discharge to the community but gender was signifi-
cantly related and males were more likely to be dis-
charged to the community than females (χ1
2 = 5.03,
p = .025).
Table 1 EAT demographics by treatment length
<5 sessions 5 sessions >5 sessions Total chi-square
Gender N= 544 840 1,080 2,464 χ2
2 = 2.93
Male 66% 69% 70% 69% p= 0.231
Female 34% 31% 30% 31%
Age @ baseline N= 544 840 1,080 2,464 χ4
2 = 14.83**
10-14 28% 23% 21% 24% p= 0.005
15-17 63% 70% 71% 68%
18-22 8% 7% 8% 8%
Race/Ethnicity N= 543 839 1,078 2,460 χ22 =7.46**
Whites 45% 43% 49% 46% P= 0.024
Non-Whites 55% 57% 51% 54%
Current Criminal Justice Involvement N= 544 839 1,079 2,462 χ22 = 38.12**
Yes 58% 58% 70% 63% p< 0.0001
Primary substance based on symptom severity N= 544 840 1,080 2,464 χ62 = 45.81**
Alcohol 12% 17% 14% 14% p< 0.0001
Amphetamines 11% 11% 6% 9%
Marijuana 41% 38% 35% 37%
Other Drug 36% 33% 45% 39%
General Individual Severity Scale N= 531 821 1,039 2,391 χ42 = 24.63**
Low - 0 53% 57% 47% 52% p< 0.0001
Moderate - 1-2 29% 30% 34% 32%
High>=3 19% 13% 19% 16%
Crime Violence Index N= 544 839 1,078 2,461 F(2,2458) = 7.72**
6.3 (±5.1) 5.7 (±4.6) 6.6 (±5.1) 6.2 (±5.0) p = 0.0005
Internal Mental Distress Scale N= 544 839 1,079 2,462 χ42 = 17.82**
0-8 65% 71% 62% 66% p< 0.001
9-23 27% 24% 31% 28%
24-44 8% 5% 7% 7%
Behavioral Complexity Scale N= 544 837 1,078 2,459 χ42 = 20.19**
0-5 34% 37% 30% 33% p<0.0001
6-18 48% 51% 54% 52%
19-33 18% 12% 16% 15%
Substance Problem Scale Past Month N= 544 839 1,079 2,462 χ42 = 13.47**
0 40% 39% 34% 37% p= 0.009
1-9 53% 57% 59% 57%
10-16 8% 4% 7% 6%
Substance Frequency Scale N= 544 840 1,080 2,464 χ42 = 40.29**
0 16% 17% 12% 14% p< 0.0001
0.01-0.13 53% 60% 52% 55%
0.14-1.00 31% 23% 36% 31%
Substance Problem Scale Past Month (3-months) N= 543 839 1,079 2,461 χ4
2 = 13.46**
0 64% 59% 57% 60% p= 0.009
1-9 34% 36% 40% 37%
10-16 2% 4% 4% 3%
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Table 1 EAT demographics by treatment length (Continued)
Substance Frequency Scale (3-months) N= 544 840 1,080 2,464 χ42 = 21.49**
0 31% 35% 32% 33% p< 0.0001
0.01-0.13 50% 54% 51% 52%
0.14-1.00 19% 11% 17% 15%
** significant at the 0.01 level.
*significant at the 0.05 level.
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were more likely to be in the youngest and oldest groups
(10–14 or 18–22; χ2
2 = 10.75, p = .005) and have lower
GISS scores (χ2
2 = 29.98, p < .001). At 3 month follow up
there were no significant differences on SPSM or SFS
scales between intake and 3 month follow up for com-
pleted clients who were discharged to the community or
transferred elsewhere.
In the multi-level mixed-effects logistic regression mod-
eling that adjusted for baseline intake scores, gender, race/
ethnicity, age, site differences (as a random effect), and
substance frequency at three months, the number of ses-
sions clients received was a significant predictor of being
discharged into the community (χ2
2 = 25.13; p < .001). SeeTable 2 EAT discharge status by baseline characteristics
Characteristic Community Other Total Chi-square
No. of sessions χ2
2 = 139.53**
N= 1,710 405 2,115 p < 0.0001
<5 sessions 82% 18%
5 sessions 93% 7%
>5 sessions 70% 30%
Gender N= 1,710 405 2,115 χ12 = 5.03*
Male 82% 18% p= 0.025
Female 78% 22%
Race/Ethnicity N = 1,708 405 2,113 χ12 = 0.74
Non-Whites 80% 20% p= 0.389
Whites 82% 18%
Age @ baseline N= 1,710 405 2,115 χ22 = 10.75**
10-14 85% 15% p= 0.005
15-17 79% 21%
18-22 85% 15%
GISS χ22 = 29.98**
N= 1,665 390 2,055 p < 0.0001
Low - 0 84% 16%
Moderate - 1-2 81% 19%
High - > =3 71% 29%
** significant at the 0.01 level.
*significant at the 0.05 level.
105 who were not discharged and 244 ASA/AMA were excluded for
this analysis.Table 3. Clients who received more than 5 sessions of
treatment were less likely to be discharged into the com-
munity compared to those who completed the protocol
number of sessions (OR: 0.35, 95% CI: 0.22 - 0.53). Clients
who received less than 5 sessions were also less likely to
be discharged into the community (OR: 0.37, 95% CI:
0.23 – 0.60) compared to those who completed the
protocol number of sessions. Gender and age did not
significantly affect discharge outcomes but whites were
more likely to be discharged to the community
(χ1
2 = 7.13, p = .007; OR: 1.52, 95% CI: 1.12-2.08)). Base-
line GISS scores were significantly associated with cli-
ents being discharged to the community. Clients with
high baseline GISS scores were less likely to be dis-
charged into the community than clients with moderate
or high severe scores (χ2
2 = 12.31, p = .002; OR: 0.90, 99%
CI: 0.65 – 1.24 and OR: 0.50, 99% CI: 0.34-0.74). When
colinearity was tested between three month follow-up
substance problem and substance frequency scores, the
correlation coefficient was 0.65, indicating some co-
linearity. The three-month SPSM score was not signifi-
cant, therefore, it was excluded from the final model.
At three month follow up higher substance frequency
scores were significantly related to discharge destination
(χ2
2 = 27.05, p < .001). Clients with the highest scores
were less likely to be discharged to the community
(OR: 0.31, 99% CI: 0.20 – 0.48).
When the effect of length of treatment on substance
abuse problems (SPSM) and average frequency of use
(SFS) was tested using multinomial logistic regression,
no significant effects were found for either variable.
Number of sessions was not a significant predictor of
three month substance abuse problems or frequency of
use after adjusting for baseline age, race, site, gender,
and severity score (GISS) at intake. Among those who
had more than 5 sessions, the risk of having a moderate
SPSM score at 3-months compared to 0 SPSM was 1.71
(95% CI: 0.75-3.89). Similarly, the relative risk ratio of
having a high SPSM score at three months relative to 0
SPSM was 0.92 (95% CI: 0.43-1.98). In looking at the
outcomes for substance abuse frequency, for the clients
who had less than 5 sessions, the relative risk ratio of
having a moderate SFS score at three months relative to
0 SFS was 0.99 (95% CI: 0.72-1.35). Similarly, the relative
risk ratio of having a high SFS score at three months
Table 3 Logistic regression results+ outcome: discharged




No. of sessions χ22 = 25.13**
5 sessions Referent p =<0.0001
<5 sessions 0.37 (0.23, 0.60)
>5 sessions 0.35 (0.22, 0.53)
Race/Ethnicity χ12 = 7.13*
p = 0.0076
Non-Whites Referent
Whites 1.52 (1.12, 2.08)
Gender χ12 = 0.52
p = 0.4688
Male Referent 0
Female 0.89 (0.66, 1.21)




15-17 1.00 (0.70, 1.43)
18-22 1.11 (0.57, 2.13)
GISS Scores χ22 = 12.31**
p = 0.0021
Low - 0 Referent 0
Moderate - 1 0.90 (0.65, 1.24)






0.01 – 0.13 0.62 (0.44 – 0.86)
0.13 – 1.00 0.31 (0.20 – 0.48)
** significant at the 0.01 level.
*significant at the 0.05 level.
105 who were not discharged and 244 ASA/AMA were excluded for
this analysis.
Mixed effects multi-level logistic regression model included covariates of race/
ethnicity, gender, age at baseline, GISS scores, and SITE as a random effect.
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who had more than 5 sessions, the relative risk ratio of
having a moderate SFS score at three months relative to
0 SFS was 1.34 (95% CI: 0.85-2.11) Similarly, the relative
risk ratio of having a high SFS score at three months
relative to 0 SFS was 1.12 (95% CI: 0.72-1.75). But, these
associations were not significant.
Of the 1,703 (among the 2,053) clients who were dis-
charged and received the 3 month follow up, approxi-
mately two-thirds (65%) reported some substance use on
the SFS scale. Clients who had no indication of either
substance problems or substance use for both scales
comprised only 33% (n = 685) of the group.Discussion
A large portion of participants (n = 1,080 of 2,464; 44%)
received more treatment than the protocol specified.
Approximately 47% of the clients who received more
than the recommended length of treatment had low
severity GISS scores at baseline. Most clients (52%) had
low severity scores. In addition, when measures of
substance problems and frequency of use at three
month follow-up were tested as outcome variables in
multinomial logistic regression analyses that adjusted
for possible confounding of other variables there was no
relationship to number of treatment sessions received.
A large proportion of clients whose level of severity was
rated moderate or low both at baseline and at three
month follow-up reported receiving more treatment
sessions than the number recommended for brief treat-
ment under the MET/CBT-5 protocol.
Discharge into the community was viewed as an indi-
cator of a positive treatment result. Although most cli-
ents were discharged into the community, discharge
patterns do not appear to be related to substance pro-
blems at three month follow-up but greater frequency of
substance use at three month follow-up was significantly
related to less likelihood of being discharged to the com-
munity. If discharge destination for additional treatment
was related to problem severity, the destination would
be appropriate and this significant relationship between
substance frequency (SFS) scores at three month follow-
up for these destinations is an indicator of appropriate
placement. Gender and age were not associated with
discharge destination. Whites were more likely to be
discharged to the community. The number of sessions
received, frequency of use at three month follow-up, and
severity of problems at baseline had the largest impact
on discharge to the community. Although sites tended
to provide more sessions to clients with higher initial
severity scores and more frequent use three months after
intake, they also routinely provided less or more than
the protocol number of sessions to clients with low and
moderate initial severity scores. There was no significant
difference in discharge of their clients to the community
based upon the increase or decrease of substance pro-
blems at 3 month follow-up. Many clients received less
than the protocol number of sessions and although most
clients in the sample (n = 2,115; 86%) were classified as
having completed treatment, some of this group
(n = 405; 19%) were transferred to additional treatment
or judicial placement.
Another indicator of a positive outcome for treatment
is a decrease in substance severity. A decrease in sub-
stance problems and frequency of use at three month
follow up should be related to more treatment for those
with greater problems. However, when a multinomial
logistic regression model controlled for race, age, gender,
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stance problems nor frequency of use were significantly
related to length of treatment.
Limitations
The study is a secondary analysis of data from the EAT
demonstration project implementing MET/CBT-5 in a
community setting. In the implementation many sites
added sessions beyond the MET/CBT-5 protocol. The
addition of sessions for many clients in this study differs
from the CYT clinical trial and demographic differences
between the samples could be a contributor to the results
with the EAT clients having a larger proportion of minor-
ity and a smaller proportion of marijuana-affected clients.
However, the demographic differences were largely due to
the intent to include diverse populations in the EAT
group to provide insight into community applications.
Client characteristics were controlled in the data analyses
to account for possible confounding influences.
Clients in the final dataset tended to be younger than
those who were excluded, more likely to be white than
minority, and more likely to have moderate as opposed
to low substance use severity. These differences would
be expected to increase the association of longer treat-
ment with substance use problems and frequency of
results at three month follow-up. However, the testing of
these relationships did not produce significant results.
Site characteristics could also influence the length of
treatment. A cultural emphasis on increasing visits to
maximize payments or staff beliefs that offering more
treatment is the best practice could lead to adding
sessions for clients. Different racial, socio-economic, or
judicial conditions of clients might also be influential. It
was not possible to determine these characteristics; there-
fore, site was treated as a nominal variable in the logistic
regression analysis and included in the multivariate ana-
lysis as a random effect. Clients are nested within sites
and the mixed-effects analyses controlled for the nesting.
The dataset did not include the number of sessions
received for many clients. The length of treatment/
number of sessions was supplied by client self-report
and could not be verified with attendance logs. Clients
may not have been able to remember exact visits or dis-
tinguish between treatment sessions and other visits.
However, their reports are a good proxy for their percep-
tion of the number of sessions received and client
reports have been shown to be fairly accurate in other
studies [23,24]. In the qualitative study it was found that
some sessions had to be split due to time pressures in
schools or individual needs. This could have added add-
itional sessions. Some sessions may have lasted longer
than suggested in the protocol or they could have been
shorter. It was known that one site requested permission
to add additional sessions for dual diagnosis clients;however, eliminating data from this site would not have
accounted for enough clients to affect the analysis. In
addition, it is possible that some clients who were classi-
fied as “completed” did not receive a final session until
after the 3 month follow-up. The significant relationship
in the multinomial logistic regression analysis of fre-
quency of use at three month follow-up to discharge to
additional care or judicial placement was an indicator
that substance use severity may have been influential in
the addition of sessions; therefore, additional multi-
nomial logistic regression analyses tested for substance
use severity as an outcome variable. When substance
problems and frequency of use were included as predic-
tors of treatment length, no significant relationship was
found for either variable to number of sessions received.
These results are further indicators of the lack of rela-
tionship between substance use and the length of treat-
ment clients received.
Although clients who left treatment against advice
had similar characteristics to the overall sample, they
included a significantly lower proportion with criminal
justice involvement and it is possible that they had less
need for additional treatment. The dataset also does not
include information on additional services clients might
have received, such as parent sessions, etc.
GAIN assessments are based on client self-reports;
however, cross-validation studies with client drug testing
have indicated a high degree of accuracy for self reports
[23]. In a study comparing adolescents entering residen-
tial treatment who had been tested with the GAIN, their
self reports were largely consistent (kappa = .53 to .69)
with family reports and urine testing on site [24].
The use of discharge status as a measure of outcome
success provides a limited view of treatment success.
Given the chronic nature of substance use, it is probable
that many clients who were discharged to the commu-
nity might need additional treatment in the future. Com-
paring the changes in client responses to the SFS and
SPSM scales between intake and 3 month follow up
and testing these scales as dependent variables in multi-
nomial logistic regression analyses and as independent
variables in the discharge analysis were mechanisms to
minimize that effect.
Although these limitations should be considered for fu-
ture research and indicate the need for replication of the
results, the dataset is large and results are consistent with
previous studies that indicate the effectiveness of brief
treatment [17]. The strength of having client data from 34
sites spread across the United States in diverse geographic
and cultural settings lends weight to the findings.
Conclusions
The challenge of implementing an evidence-based prac-
tice in a community setting is substantial and this study
Riley et al. Substance Abuse Treatment, Prevention, and Policy 2012, 7:35 Page 11 of 12
http://www.substanceabusepolicy.com/content/7/1/35provides an indication of areas that need particular at-
tention. Findings indicate that adding sessions was not
necessary for many clients and may have added cost
to treatment.
The length of treatment that clients received did not
appear to be based on client needs for the majority of
the sites. As the qualitative study [14] suggested, site
norms may have a larger impact on implementation than
a manualized protocol [14,25-27]. For the sites in this
study that provided more than 5 sessions to 72% of their
clients, the decision to provide more sessions seems to
have been made at the site level, irrespective of the
instructions in their manuals and their training. If there
are beliefs that more treatment is better and more reim-
bursement is provided for additional sessions, it is likely
that clients will receive more sessions. The results of this
study suggest that use of the GISS scale to determine
the potential need for additional sessions might be a
helpful screening tool.
Monitoring implementation needs to be ongoing;
otherwise, community implementation will not replicate
the results obtained in randomized clinical trials. Moni-
toring is tricky; however, since the use of supervisory
time has associated cost and there is a tendency for
supervision to decrease over time [14]. Can less expen-
sive methods be used; e.g., web-based checklists, self-
reports, peer reviews of audiotapes?
Experienced counselors may become bored with manua-
lized treatment and they may stray from protocols [14].
Changes to provide cultural sensitivity can create a posi-
tive atmosphere for client change [28]. On the other hand,
we also know that evidence-based manualized interven-
tions obtain better results than “business as usual” [26].
How far can treatment of individual needs of staff and
clients stretch the protocol without harming the out-
comes? Although an innovation may not be implemen-
ted with fidelity, we do not know which adaptations are
harmless in affecting outcomes and which ones are crit-
ical to effective intervention with adolescents. Without
segmenting and testing the components of an interven-
tion, it will not be possible to determine which ones
have an effect on outcomes and which ones are more
effective with certain types of clients.
More research is needed to identify the key variables
to implement evidence-based models of treatment for
alcohol and drug use disorders. Research also needs to
identify protocol variables that can be modified without
interfering with therapeutic outcomes. These efforts
will require increased funding for empirical research on
substance abuse treatment.
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